Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fisons licensing agreements include deal for Ciba's iralukast; RPR closing in on takeover.

Executive Summary

FISONS AND CIBA TO COLLABORATE ON IRALUKAST DEVELOPMENT FOR ASTHMA, Fisons announced Sept. 29. Under the agreement, the companies will collaborate on development and marketing of Ciba's leukotriene d4 antagonist iralukast in a powder formulation for delivery via Fisons' Ultrahaler delivery system. "The arrangements between the parties contemplate and provide for the possibility of further cooperation in relation to follow-up compounds, devices and alternative delivery systems," Fisons added. Iralukast will begin Phase III trials in 1996, Ciba said; the Swiss firm plans to introduce a formulation using its own single-dose dry powder device before completing development of the Ultrahaler formulation.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel